Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Vet Med Sci ; 10(3): e1393, 2024 05.
Article in English | MEDLINE | ID: mdl-38640108

ABSTRACT

BACKGROUND: Various anti-parasitic drugs are used to control donkey parasitic diseases. The abuse of donkey drugs leads to the disposition of residues in the edible parts of treated donkeys. OBJECTIVES: The aim of this study was to (1) analyse the pharmacokinetics of ABZSO to serve as reference for the dosage regimen in donkey; and (2) calculate the withdrawal times of the ABZSO in the tissue of the donkey. METHODS: The concentrations of ABZSO and its metabolites in plasma and tissues were determined using high-performance liquid chromatography with an ultraviolet detector. Pharmacokinetic analysis was performed by the programme 3p97. RESULTS: The plasma concentrations of ABZSO and ABZSO2 concentration-time data in donkey conformed to the absorption one-compartment open model. The t 1 / 2 k e ${{{t1}} \!\mathord{/ {\vphantom { {2{{k}_{\mathrm{e}}}}}}}}$ of ABZSO was 0.67 h, whereas the t1/2 k e was 12.93 h; the Cmax and the Tp were calculated as 0.58 µg mL-1 and 3.01 h. The Vd/F of ABZSO was estimated to be 10.92 L kg-1; the area under the curve (AUC) was 12.81 µg mL-1 h. The Cmax and AUC values of ABZSO were higher than those of ABZSO2; however, t1/2 K e and Vd/F were lower. Other pharmacokinetics parameters were similar between the two metabolites. CONCLUSIONS: The results revealed that ABZSO2 was the main metabolite of ABZSO in donkey plasma. The concentrations of ABZSO and its chief metabolite (ABZSO2) were detected in liver, kidney, skin and muscle; however, ABZ-SO2NH2 was only detected in liver and kidney. The results also revealed that the depletion of ABZSO and its metabolite in donkey was longer, especially in skin.


Subject(s)
Albendazole/analogs & derivatives , Anthelmintics , Animals , Anthelmintics/pharmacokinetics , Injections, Intramuscular/veterinary , Equidae/metabolism , Albendazole/pharmacokinetics
2.
J Vet Med Sci ; 84(6): 777-783, 2022 Jun 10.
Article in English | MEDLINE | ID: mdl-35491103

ABSTRACT

Encephalitozoon cuniculi (E. cuniculi) is a microsporidian parasite commonly detected in rabbits and can infect humans and cause encephalitozoonosis. And Toxoplasma gondii is a prevalent parasite distributed worldwide and can infect almost all warm-blooded animals, including humans. The aim of the current study was to investigate the seroprevalence of E. cuniculi and Toxoplasma gondii, and risk factors of infection in pet rabbits reared in eastern coastal areas of China (Tianjin, Shandong, Jiangsu, Zhejiang, Shanghai and Fujian). Total 222 blood samples of pet rabbits were collected from local veterinary hospitals. The seropositivity rates of E. cuniculi were 16.22% (36/222) according to an Enzyme-linked immunosorbent assay (ELISA). Female pet rabbits was significantly higher than that in males (P=0.002), Zhejiang were markedly higher than those in Jiangsu and Shanghai (P=0.017, P=0.022), and cross-breed rabbits were dramatically higher than those in Chinchilla, New Zealand white, Rex (P=0.02, P=0.006, P=0.008). The seroprevalence of T. gondii was 13.06% (29/222) by the method of ELISA. The seroprevalence in Zhejiang was significantly higher than that in Shanghai (P=0.017). No difference in seroprevalence was detected with respect to the gender, age, species, health status, or season. These findings show that E. cuniculi and T. gondii are present and spread in pet rabbits. Therefore, pet rabbits should be considered as an important reservoir of encephalitozoonosis for humans and maybe important implication for public health in eastern coastal areas of China.


Subject(s)
Encephalitozoon cuniculi , Encephalitozoonosis , Toxoplasma , Animals , Antibodies, Fungal , Antibodies, Protozoan , China/epidemiology , Encephalitozoonosis/epidemiology , Encephalitozoonosis/veterinary , Female , Male , Plant Breeding , Rabbits , Seroepidemiologic Studies
3.
J Cell Physiol ; 234(12): 22331-22342, 2019 12.
Article in English | MEDLINE | ID: mdl-31140597

ABSTRACT

Ovarian cancer characterizes as the fourth leading consequence of death associated with cancer for women. Accumulating evidence underscores the vital roles of microRNAs (miRNAs) in preventing ovarian cancer development. Besides, induction of the phosphatidylinositol-3 kinase/serine/threonine kinase (PI3K/Akt) pathway associated with the ovarian cancer cell migration and invasion. The study aims to examine the effects of miR-15b on the proliferation, apoptosis, and senescence of human ovarian cancer cells by binding to lysophosphatidic acid receptor 3 (LPAR3) with the involvement of the PI3K/Akt pathway. The positive expression of LPAR3 protein was detected by immunohistochemistry. Then the interaction between miR-15b and LPAR3 was examined. The possible role of miR-15b in ovarian cancer was explored using gain- and loss-of-function experiments. Subsequently, the functions of miR-15b on PI3K/Akt pathway, proliferation, migration, invasion, senescence and apoptosis of ovarian cancer cells were assessed. Furthermore, in vivo tumorigenicity assay in nude mice was performed. LPAR3 was overexpressed, whereas miR-15b was poorly expressed in ovarian cancer tissues. LPAR3 is a direct target of miR-15b. Restored miR-15b promoted Bax expression, apoptosis, and senescence, inhibited expression of LPAR3 and Bcl-2, the extent of PI3K and Akt phosphorylation, as well as ovarian cancer cell proliferation, migration, and invasion. Further, tumor growth was observed to be prevented by miR-15b overexpression. Collectively, our study demonstrates that miR-15b represses the proliferation and drives the senescence and apoptosis of ovarian cancer cells through the suppression of LPAR3 and the PI3K/Akt pathway, highlighting an antitumorigenic role of miR-15b.


Subject(s)
Gene Expression Regulation, Neoplastic , Ovarian Neoplasms/genetics , Receptors, Lysophosphatidic Acid/metabolism , Up-Regulation/genetics , Adult , Aged , Animals , Cell Line, Tumor , Cell Movement/genetics , Cell Proliferation/genetics , Female , Humans , Mice, Nude , MicroRNAs/genetics , MicroRNAs/metabolism , Middle Aged , Neoplasm Invasiveness , Ovarian Neoplasms/pathology , Phosphatidylinositol 3-Kinases/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Signal Transduction
4.
Wei Sheng Wu Xue Bao ; 50(4): 506-11, 2010 Apr.
Article in Chinese | MEDLINE | ID: mdl-20560354

ABSTRACT

OBJECTIVE: Interleukin-18 (IL-18) is a proinflammatory cytokines that plays a key role of immune regulation through activating the Th 1 cell and NK cell secreting interferon-gamma (IFN-gamma). IL-18-binding proteins(IL-18BP) secreted in human and mouse can antagonise the activity of IL-18. The homologue gene of IL-18BP from fowlpox virus genome was predicted and identified of its expressed protein, to use as an antagonist to IL-18 guiding disease. METHODS: The cIL-18BP gene was isolated from the genome of fowlpox vaccine virus by PCR through a pair of special primers and cloned into vectors pPICZalphaA, then expressed in yeast GS115. The biologic activity of recombinant proteins binding with cIL-18 was measured, inhibiting the activity of cIL-18 enhancing relative cells secreting IFN-gamma was confirmed through ELISA. RESULTS: The cIL-18BP gene was cloned from fowlpox virus and acquired high performance expression in yeast systems induced with methanol identified by SDS-PAGE. Recombinant cIL-18BP purified can bind specifically with recombinant cIL-18 determined by ELISA test. cIL-18BP can antagonise the activity of cIL-18 with determining the IFN-gamma concentration secreting in PBMCs and MSB1 cells stimulated by cIL-18 respectively. CONCLUSION: The experiment indicates that recombinant cIL-18BP can inhibit the activity of cIL-18 stimulating related immune cells secreting IFN-gamma. Deletion of the cIL-18BP from virus may improve the safety and immunogenicity of fowlpox virus vaccine.


Subject(s)
CD59 Antigens/immunology , Fenofibrate/antagonists & inhibitors , Intercellular Signaling Peptides and Proteins/pharmacology , Interferon-gamma/antagonists & inhibitors , Interleukin-18/physiology , Animals , Carrier Proteins , Humans , Intercellular Signaling Peptides and Proteins/metabolism , Interleukin-18/metabolism , Mice , Recombinant Proteins/genetics , Recombinant Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...